Aptahem AB (publ) (NGM: APTA)

Market Cap	6.49M
Revenue (ttm)	1.93M
Net Income (ttm)	-9.96M
Shares Out	5.67M
EPS (ttm)	-2.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,224
Open	1.130
Previous Close	1.180
Day's Range	1.090 - 1.210
52-Week Range	1.090 - 14.900
Beta	1.17
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 12, 2025

About Aptahem AB

Aptahem AB (publ), a clinical stage biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. Its principal pharmaceutical candidate is Apta-1, which is in preclinical stage to prevent mortality rate caused by organ and tissue damage in sepsis patients. The company has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children’s Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in M...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 4
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: APTA

Financial Performance

In 2023, Aptahem AB's revenue was 2.63 million, a decrease of -23.71% compared to the previous year's 3.45 million. Losses were -11.11 million, 25.4% more than in 2022.